Bill Walsh Translational Cancer Research Laboratory

The Bill Walsh Translational Cancer Research Laboratory is the research arm of the Medical Oncology Department at Royal North Shore Hospital.

We focus on increasing our understanding of cancer biology and how cancer will behave. We are also working to identify better ways to diagnose cancer.

Through our research we are improving cancer treatment and offering better outcomes for those with the disease.


Associate Professor Nick PavlakisProfessor Nick Pavlakis BSc, MBBS, MMed (Clin. Epi), PhD, FRACP

Appointment: Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Positions: Co-head, Bill Walsh Translational Cancer Research Laboratory; Chair, Scientific Advisory Committee, Australasian Lung Cancer Trials Group , Senior Staff Specialist, Dept. of Medical Oncology Royal North Shore

Professor Stephen Clarke OAM, MBBS, PhD, MD, FRACP, FAChPM

Appointment: Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Positions: Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist in Dept. Medical Oncology, Royal North Shore Hospital

Associate Professor Helen Wheeler MBBS, FRACP

Position: Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist, Head Dept. Medical Oncology, Royal North Shore Hospital

Appointment: Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Position: Laboratory Research Director, Bill Walsh Translational Cancer Research Laboratory; Co-Lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre


Dr Emily Colvin BMedSc (Hons), PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Proud Family Fellow and Cancer Institute NSW Early Career Fellow
Group Leader: Ovarian Cancer

Dr Connie Diakos Associate Professor Connie Diakos BSc(Hons), PhD, MBBS, FRACP, MRACI CChem

Appointment: Conjoint Senior Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Research Fellow; Co-lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre.
Group Leader: Colorectal Cancer, Neuroendocrine Cancer

Dr Amanda Hudson Dr Amanda Hudson BSc (Hons), PhD

Appointment: Research Fellow, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: The Brain Cancer Group Fellow
Group Leader: Brain Cancer

Dr Sumit Sahni Dr Sumit Sahni B.Pharma, PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, University of Sydney
Position: Boncardo Pancreatic Cancer Research Fellow
Group Leader: Pancreatic Cancer

Ms Shihani Stoner MPhil, MSc, BSc  

Appointment: Operations Manager, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney

Position: Operations Manager                                                                    Group Leader: Preclinical Pipeline for Advancing Cancer Therapeutics (PACT)

 Sooin Byeon – Research Assistant

Taymin du Toit-Thompson – PhD Student

Shafi Alenizi - PhD Student

Farah Abu Al-Hial - Research Officer

Nada Cheikh-Ali - Clinical Researcher 

Heidi Tsang - Clinical Research Associate

Carolyn Kwong - Clinical Research Officer

Saurabh Satijah - Research Affiliate 

Julius Kim - Mark Hughes Brain Cancer Research Fellow

Hasanthi De Silva - Senior Research Officer

Aude Touffu - Research Assistant

Fern Williams - Research Assistant

Evan Gauci - Honours Student 

Liz Millar - Research Assistant

Sara Mokhtar - Research Assistant 

Helen Kong - Research Assistant

Narjis Fatima  - Postdoctoral Research Associate

Hye Soo Lee - Medical Placement Student

Brain Cancer:

  1. Teaching an Old Drug New Tricks: Can we repurpose an old drug as a new brain cancer treatment?
  2. The immuno-coagulome: an untapped pathway for new therapeutics in glioma
  3. Investigating how glioblastoma tumours change over time to become resistant to treatment
  4. Unravelling the tumour micro-environment to combat brain cancer
  5. Laying the foundations for improved treatments for IDH-mutated glioma
  6. The interaction between coagulation, angiogenesis and inflammatory pathways in glioblastoma
  7. MHF Brain Cancer PACT: Mark Hughes Foundation Collaborative Brain Cancer Pre-clinical pipeline for Advancing Cancer Therapeutics
  8. Development of non-invasive monitoring for brain tumour recurrence and treatment resistance
  9. A new class of theranostics for malignant brain cancer
  10. Radiosensitisation of high-grade gliomas by modulating glucose metabolism
  11. New Horizons: Therapeutic applications for medicinal cannabis in the treatment of brain cancer

Colorectal Cancer:

  1. The role ofIinflammation in colorectal cancer
  2. Identifying prognostic protein markers in colorectal cancer tumour
  3. Exploring a new nanotechnology strategy for the neo-adjuvant treatment of colorectal cancer by photodynamic therapy and ionising radiation

Lung Cancer:

  1. Investigating patterns of drug resistance in ALK rearranged non-small cell lung cancer
  2. Exploring methods to improve efficacy of immunotherapy in non-small cell lung cancer
  3. Identification of biomarkers for non-small cell lung cancer
  4. Chemotherapy resistance in non-small cell lung cancer
  5. The exhaled breath condensate proteome: a promising source of biomarkers for lung cancer

Mesothelioma:

  1. Improved treatment for mesothelioma: Can cannabinoids address this unmet need?

Neuroendocrine Tumours:

  1. The role of dual PET scans in understanding neuroendocrine tumour behaviour
  2. Analysing PET scans for neuroendocrine tumours

Ovarian Cancer:

  1. Evaluation of lysyl oxidase inhibitors as a new treatment for ovarian cancer
  2. Investigating the role of long non-coding RNA (ribonucleic acid) in the ovarian cancer microenvironment
  3. Improving ovarian cancer treatment using nanoparticles

Pancreatic Cancer:

  1. Biomarker identification for pancreatic cancer diagnosis
  2. Biomarker identification for pancreatic cancer prognosis.
  3. Identification of new drug targets for pancreatic cancer treatment
  4. Understanding the role of tumour microenvironment in pancreatic cancer progression

Events, News and Seminars

Kolling Research Symposium 2024

Kolling Research Symposium 2024

We would like to thank everyone involved in the 2024 Kolling Institute Symposium. During the event, ..... Read more

Category: Cardiovascular and Renal Research, Musculoskeletal Research, Neuroscience and Pain Research, Presentations, Research Excellence

Kolling NEWS

Kolling NEWS

Our Kolling Institute newsletter brings together a collection of profiles on our impressive research..... Read more

Category: New Treatment, Newsletters, Research Excellence

Spotlight on clinical trials

Spotlight on clinical trials

Kolling Institute researcher and Royal North Shore Hospital endocrinologist Professor Rory Clifton-B..... Read more

Category: New Treatment, Research Excellence